The two companies have worked in close collaboration since Liv was founded in 2016. Liv Diagnostics is currently a part of AstraZeneca’s bioventure hub. As Cline Scientific strengthens their research and development efforts, the purpose of the acquisition is to simplify and accelerate the development of Liv’s diagnostic product.

Liv has developed an advanced early detection technology that can analyze tumor cells isolated from breast cancer patients to determine the risk of metastasis with higher precision than current methods available. As of today, there is no diagnostic tool to directly measure the breast cancer tumors’ ability to migrate and metastasize to distant organs such as the brain. This information is critical as metastasis is responsible for 90% of all cancer related deaths.

“I am excited to be involved in the continued development of this technology together with Cline as we currently have no sure means to treat metastatic disease. With this diagnostic tool we will be in a much better place to accurately diagnose, and thus correctly treat, patients at risk of this devastating disease.” Breast cancer researcher Theresa Vincent, Ph D, Principal Investigator New York University & Uppsala University

Cline Scientific and Liv Diagnostics believe this acquisition will not only help expedite the development of their product, but help move it towards clinical approval and increase the possibility for successful implementation. 

“After three years of being apart of a project that has resulted in the development of Liv Diagnostics, we are very excited to help play an even bigger key role in improving cancer care. Cline will now take over Liv Diagnostics, with the goal to take the company and the project to a point where we can speed up the development of the existing product and reduce fatalities among breast cancer patients.” says Cline Scientific CEO, President and co-founder Patrik Sundh. 

Liv Diagnostics’ team is comprised of cancer researchers from world renowned research institutions such as the Weill Cornell Medicine, New York University, Karolinska Institute, University of Gothenburg and Uppsala University. Recently Liv Diagnostic completed a pre-clinical study that showed their prototype is highly accurate at being able to detect the level of aggressiveness between tumor cells.

”Liv developed a very promising prototype that is now ready for the first clinical tests, which is an important milestone in the R&D process. The acquisition by Cline will advance the development of the product, and I’m confident that it will create great benefits for patients and health care.” says Liv Diagnostics CEO and co-founder Johan Bjurquist

About Cline Scientific AB:

Cline Scientific is a Life Science company that sells proprietary research products and collaborates with industry players by jointly utilizing their products developed from their patented nanotechnology to control the functions of human cells in the laboratory. With Cline’s technology, it is possible to use stem cells safely to cure serious illnesses and to measure the ability of cancer tumors to spread for diagnostic purposes.

Cline Scientific AB  
Argongatan 2C
431 53  Mölndal 

Telefon: 031-387 55 55 
E-post: info@clinescientific.com 
Hemsida: www.clinescientific.com 

This is information that Cline Scientific AB is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 7 November 2019.